Comparative effectiveness of 2 β-blockers in hypertensive patients

Archives of Internal Medicine

Volumn 172, Issue 18, 2012, Pages 1406-1412

  Parker, Emily D ^a   Margolis, Karen L ^a   Trower, Nicole K ^a   Magid, David J ^b   Tavel, Heather M ^b   Shetterly, Susan M ^b   Ho, P Michael ^c   Swain, Bix E ^d   O'Connor, Patrick J ^a  

^a Health Partners Institute for Education and Research   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; METOPROLOL TARTRATE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEALTH CARE PLANNING; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TREATMENT OUTCOME;

EID: 84867371820     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.4276     Document Type: Article

References (35)

1. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-1535.
2. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997;277(9):739-745. (Pubitemid 27106227)
3. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? a systematic review. JAMA. 1998;279(23):1903-1907. (Pubitemid 28299288)
4. Mancia G, De Backer G, Dominiczak A, et al; The task force for the management of arterial hypertension of the European Society of Hypertension; The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. Eur Heart J. 2007;28(12):1462-1536.
5. Chobanian AV, Bakris GL, Black HR, et al National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572. (Pubitemid 37430158)
6. Dahlöf B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
7. Dahlöf B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
8. Messerli FH, Beevers DG, Franklin SS, Pickering TG. beta-Blockers in hypertension-the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension. Am J Hypertens. 2003;16(10):870-873. (Pubitemid 37204686)
9. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? a meta-analysis. Lancet. 2005;366(9496):1545-1553. (Pubitemid 41540112)
10. Ong HT. Beta blockers in hypertension and cardiovascular disease. BMJ. 2007;334(7600):946-949. (Pubitemid 46808392)
11. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007;(1):CD002003.
12. Beevers DG. The end of beta blockers for uncomplicated hypertension? Lancet. 2005;366(9496):1510-1512. (Pubitemid 41540100)
13. Massie BM. Review: available evidence does not support the use of beta blockers as first line treatment for hypertension. Evid Based Med. 2007;12(4):112. (Pubitemid 47315898)
14. Reid JL. Optimal features of a new beta-blocker. Am Heart J. 1988;116(5, pt 2):1400-1404.
15. Drayer DE. Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers. Pharmacotherapy. 1987;7(4):87-91. (Pubitemid 18002074)
16. Ho PM, Zeng C, Tavel HM, et al. Trends in first-line therapy for hypertension in the Cardiovascular Research Network Hypertension Registry, 2002-2007. Arch Intern Med. 2010;170(10):912-913.
17. Magid DJ, Shetterly SM, Margolis KL, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors versus beta-blockers as second-line therapy for hypertension. Circ Cardiovasc Qual Outcomes. 2010;3(5):453-458.
18. Schmittdiel J, Selby JV, Swain B, et al. Missed opportunities in cardiovascular disease prevention? low rates of hypertension recognition for women at medicine and obstetrics-gynecology clinics. Hypertension. 2011;57(4):717-722.
19. Selby JV, Lee J, Swain BE, et al. Trends in time to confirmation and recognition of new-onset hypertension, 2002-2006. Hypertension. 2010;56(4):605-611.
20. Selby JV, Peng T, Karter AJ, et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care. 2004;10(2, pt 2):163-170. (Pubitemid 38332390)
21. Ray WA. Evaluatingmedication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920. (Pubitemid 37323253)
22. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2)(suppl 1):S1-S266.
23. Parsons L. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. In: Proceedings of the Twenty-sixth Annual SAS Users Group International Conference. Cary, NC: SAS Institute Inc; 2001:214-226.
24. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356(9246):1955-1964.
25. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed). 1986;293(6555):1145- 1151. (Pubitemid 16008923)
26. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed). 1985;291(6488):97-104.
27. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens. 1985;3(4):379-392.
28. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304(6824):405-412.
29. National Institute for Health and Clinical Excellence. Hypertension: Clinical Management of Primary Hypertension in Adults. London, England: National Institute for Health and Clinical Excellence; 2011. NICE Clinical Guideline 127.
30. Weber MA. The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens. 2005;18(12, pt 2):169S-176S. (Pubitemid 41803605)
31. Wikstrand J, KendallM. The role of beta receptor blockade in preventing sudden death. Eur Heart J. 1992;13(suppl D):111-120.
32. Sandrone G, Mortara A, Torzillo D, La Rovere MT, Malliani A, Lombardi F. Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarction. Am J Cardiol. 1994;74(4):340-345. (Pubitemid 24253470)
33. Tuininga YS, Crijns HJ, Brouwer J, et al. Evaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patients. Circulation. 1995;92(12):3415-3423.
34. Psaty BM, Siscovick DS. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. JAMA. 2010;304(8):897-898.
35. Kottke T, Baechler C, Parker E. The accuracy of heart disease prevalence estimated from claims data compared to electronic health record. Prev Chronic Dis. 2012;9:E141.